{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T06:51:17Z","timestamp":1784875877919,"version":"3.55.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":2531,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2019,2,15]],"date-time":"2019-02-15T00:00:00Z","timestamp":1550188800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Plan Andaluz de Investigacion from the Consejeria de Salud de la Junta de Andalucia, Spain","award":["AGR-277"],"award-info":[{"award-number":["AGR-277"]}]},{"name":"Virbac SL"},{"name":"Plan Andaluz de Investigacion from the Consejeria de Salud de la Junta de Andalucia, Spain","award":["AGR-277"],"award-info":[{"award-number":["AGR-277"]}]},{"name":"Virbac SL"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Nonsteroidal anti-inflammatory drugs are administered in horses for several systemic diseases. Selective cyclooxygenase-2 inhibitors are preferred because of lower risk of adverse effects. Several meloxicam formulations have been tested in horses, but a recently marketed granule oral formulation has not been studied.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To characterize the pharmacokinetics of a novel granule meloxicam formulation in fasted and fed horses, and to compare pharmacokinetic features with oral suspension and tablets.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Animals<\/jats:title>\n                    <jats:p>Seven healthy adult horses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Meloxicam was administered at 0.6 mg\/kg in fasted or fed horses. Blood samples were collected for pharmacokinetic analysis, and vital signs, hematology, and biochemistry variables were monitored for 72\u2009hours.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>No adverse effects were detected. Volume of distribution and clearance after intravenous administration of meloxicam were 0.36\u2009L\/kg and 29.12\u2009mL\/h\/kg, respectively, with a 12.39\u2009hours of terminal half-life. Protein binding was of 97%. Bioavailability was high for every oral formulation, ranging 70%-110%, without feed effect. Because of a slower absorption, meloxicam after administration of granules had a longer half-life (24 and 34\u2009hours, fasted and fed, respectively) and mean residence time (31 and 47\u2009hours), than suspension and tablets (ranging 10-13 and 13-15\u2009hours, respectively). In addition, the time above therapeutic concentration was higher for the granule formulation than other formulations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Clinical Importance<\/jats:title>\n                    <jats:p>Granule formulation has different PK parameters compared to other oral formulations, which could enable this formulation to be used for different dosage regimens in order to reach a desired clinical effect or decrease the risk of adverse effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jvim.15433","type":"journal-article","created":{"date-parts":[[2019,2,15]],"date-time":"2019-02-15T10:01:30Z","timestamp":1550224890000},"page":"961-967","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Pharmacokinetics of meloxicam after oral administration of a granule formulation to healthy horses"],"prefix":"10.1093","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7725-8080","authenticated-orcid":false,"given":"Francisco Javier","family":"Mendoza","sequence":"first","affiliation":[{"name":"University of Cordoba Department of Animal Medicine and Surgery, , Cordoba,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5817-5514","authenticated-orcid":false,"given":"Juan Manuel","family":"Serrano-Rodriguez","sequence":"additional","affiliation":[{"name":"Toxicology and Legal and Forensic Medicine, University of Cordoba Department of Pharmacology, , Cordoba,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Perez-Ecija","sequence":"additional","affiliation":[{"name":"University of Cordoba Department of Animal Medicine and Surgery, , Cordoba,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,3,1]]},"reference":[{"key":"2026020922233269500_jvim15433-bib-0001","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1365-2885.2004.00617.x","article-title":"Pharmacodynamics and pharmacokinetics of nonsteroidal anti-inflammatory drugs in species of veterinary interest","volume":"27","author":"Lees","year":"2004","journal-title":"J Vet Pharmacol Ther"},{"key":"2026020922233269500_jvim15433-bib-0002","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/vec.12271","article-title":"The use of nonsteroidal anti-inflammatory drugs in critically ill horses","volume":"25","author":"Cook","year":"2015","journal-title":"J Vet Emerg Crit Care"},{"key":"2026020922233269500_jvim15433-bib-0003","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.2460\/javma.250.11.1271","article-title":"Update on the use of cyclooxygenase-2-selective nonsteroidal anti-inflammatory drugs in horses","volume":"250","author":"Ziegler","year":"2017","journal-title":"J Am Vet Med Assoc"},{"key":"2026020922233269500_jvim15433-bib-0004","doi-asserted-by":"crossref","first-page":"992","DOI":"10.2460\/ajvr.70.8.992","article-title":"Effect of firocoxib or flunixin meglumine on recovery of ischemic-injured equine jejunum","volume":"70","author":"Cook","year":"2009","journal-title":"Am J Vet Res"},{"key":"2026020922233269500_jvim15433-bib-0005","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1111\/j.1939-1676.2012.01004.x","article-title":"Effects of meloxicam and phenylbutazone on equine gastric mucosal permeability","volume":"26","author":"D'Arcy-Moskwa","year":"2012","journal-title":"J Vet Intern Med"},{"key":"2026020922233269500_jvim15433-bib-0006","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1046\/j.1365-2885.2002.00436.x","article-title":"Pharmacodynamics and enantioselective pharmacokinetics of racemic carprofen in the horse","volume":"25","author":"Lees","year":"2002","journal-title":"J Vet Pharmacol Ther"},{"key":"2026020922233269500_jvim15433-bib-0007","doi-asserted-by":"crossref","first-page":"614","DOI":"10.2460\/ajvr.68.6.614","article-title":"Effects of the cyclooxygenase inhibitor meloxicam on recovery of ischemia-injured equine jejunum","volume":"68","author":"Little","year":"2007","journal-title":"Am J Vet Res"},{"key":"2026020922233269500_jvim15433-bib-0008","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s12917-015-0427-4","article-title":"Evaluation of the efficacy of meloxicam for post-operative management of pain and inflammation in horses after orthopaedic surgery in a placebo controlled clinical field trial","volume":"11","author":"Walliser","year":"2015","journal-title":"BMC Vet Res"},{"key":"2026020922233269500_jvim15433-bib-0009","first-page":"730","article-title":"Pharmacokinetics and bioequivalence of 2 meloxicam oral dosage formulations in healthy adult horses","volume":"56","author":"Vivancos","year":"2015","journal-title":"Can Vet J"},{"key":"2026020922233269500_jvim15433-bib-0010","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/0007-1935(91)90099-9","article-title":"Pharmacodynamics and pharmacokinetics of miloxicam in the horse","volume":"147","author":"Lees","year":"1991","journal-title":"Br Vet J"},{"key":"2026020922233269500_jvim15433-bib-0011","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.2460\/ajvr.2004.65.1542","article-title":"Pharmacokinetics of meloxicam in plasma and urine of horses","volume":"65","author":"Toutain","year":"2004","journal-title":"Am J Vet Res"},{"key":"2026020922233269500_jvim15433-bib-0012","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.2460\/ajvr.2004.65.1533","article-title":"Pharmacokinetic-pharmacodynamic relationships and dose response to meloxicam in horses with induced arthritis in the right carpal joint","volume":"65","author":"Toutain","year":"2004","journal-title":"Am J Vet Res"},{"key":"2026020922233269500_jvim15433-bib-0013","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.2460\/ajvr.67.6.1082","article-title":"Comparative pharmacokinetics of meloxicam in clinically normal horses and donkeys","volume":"67","author":"Sinclair","year":"2006","journal-title":"Am J Vet Res"},{"key":"2026020922233269500_jvim15433-bib-0014","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jevs.2010.09.004","article-title":"Evaluation of pharmacokinetic-pharmacodynamic relationships for BioRelease meloxicam formulations in horses","volume":"30","author":"Burns","year":"2010","journal-title":"J Equine Vet Sci"},{"key":"2026020922233269500_jvim15433-bib-0015","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1111\/j.1939-1676.2012.00976.x","article-title":"Pharmacokinetics and safety of single and multiple oral doses of meloxicam in adult horses","volume":"26","author":"Noble","year":"2012","journal-title":"J Vet Intern Med"},{"key":"2026020922233269500_jvim15433-bib-0016","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/jvp.12021","article-title":"Pharmacokinetics and adverse effects of oral meloxicam tablets in healthy adult horses","volume":"36","author":"Vander Werf","year":"2013","journal-title":"J Vet Pharmacol Ther"},{"key":"2026020922233269500_jvim15433-bib-0017","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/jvim.12045","article-title":"Pharmacokinetics and safety of oral administration of meloxicam to foals","volume":"27","author":"Raidal","year":"2013","journal-title":"J Vet Intern Med"},{"key":"2026020922233269500_jvim15433-bib-0018","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/jvp.12461","article-title":"Postoperative pharmacokinetics of meloxicam in horses after surgery for colic syndrome","volume":"41","author":"Di Salvo","year":"2017","journal-title":"J Vet Pharmacol Ther"},{"key":"2026020922233269500_jvim15433-bib-0019","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.cmpb.2016.01.013","article-title":"A diagnostic tool for population models using non-compartmental analysis: the ncappc package for R","volume":"127","author":"Acharya","year":"2016","journal-title":"Comput Methods Programs Biomed"},{"key":"2026020922233269500_jvim15433-bib-0020","first-page":"41","article-title":"Veterinary Pharmacology and Therapeutics","author":"Riviere","year":"2018","edition":"10"},{"key":"2026020922233269500_jvim15433-bib-0021","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.phrs.2005.04.004","article-title":"COX-1 and COX-2 inhibition in horse blood by phenylbutazone, flunixin, carprofen and meloxicam: an in vitro analysis","volume":"52","author":"Beretta","year":"2005","journal-title":"Pharmacol Res"},{"key":"2026020922233269500_jvim15433-bib-0022","first-page":"576","article-title":"Pharmacokinetics of meloxicam in animals and the relevance to humans","volume":"26","author":"Busch","year":"1998","journal-title":"Drug Metab Dispos"},{"key":"2026020922233269500_jvim15433-bib-0023","first-page":"1","article-title":"Equine Pharmacology","author":"Maxwell","year":"2014","edition":"1"},{"key":"2026020922233269500_jvim15433-bib-0024","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/jvp.12177","article-title":"Pharmacokinetics and pharmacodynamics of three formulations of firocoxib in healthy horses","volume":"38","author":"Holland","year":"2015","journal-title":"J Vet Pharmacol Ther"},{"key":"2026020922233269500_jvim15433-bib-0025","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.2460\/ajvr.2001.62.1755","article-title":"In vitro effects of cyclooxygenase inhibitors in whole blood of horses, dogs, and cats","volume":"62","author":"Brideau","year":"2001","journal-title":"Am J Vet Res"},{"key":"2026020922233269500_jvim15433-bib-0026","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.tvjl.2011.03.016","article-title":"In vitro and ex vivo pharmacodynamics of selected non-steroidal anti-inflammatory drugs in equine whole blood","volume":"191","author":"Cuniberti","year":"2012","journal-title":"Vet J"},{"key":"2026020922233269500_jvim15433-bib-0027","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.2460\/ajvr.1999.60.11.1441","article-title":"Pharmacokinetics of flunixin meglumine in donkeys, mules, and horses","volume":"60","author":"Coakley","year":"1999","journal-title":"Am J Vet Res"},{"key":"2026020922233269500_jvim15433-bib-0028","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1046\/j.1365-2885.1999.00219.x","article-title":"Pharmacokinetics and bioequivalence of two suxibuzone oral dosage forms in horses","volume":"22","author":"Jaraiz","year":"1999","journal-title":"J Vet Pharmacol Ther"},{"key":"2026020922233269500_jvim15433-bib-0029","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.tvjl.2013.04.019","article-title":"Pharmacokinetics, pharmacodynamics, metabolism, toxicology and residues of phenylbutazone in humans and horses","volume":"196","author":"Lees","year":"2013","journal-title":"Vet J"},{"key":"2026020922233269500_jvim15433-bib-0030","year":"2018"},{"key":"2026020922233269500_jvim15433-bib-0031","doi-asserted-by":"crossref","first-page":"54","DOI":"10.2460\/ajvr.2001.62.54","article-title":"Effects of anti-inflammatory drugs on lipopolysaccharide-challenged and -unchallenged equine synovial explants","volume":"62","author":"Moses","year":"2001","journal-title":"Am J Vet Res"},{"key":"2026020922233269500_jvim15433-bib-0032","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2746\/042516409X436286","article-title":"In vivo effects of meloxicam on inflammatory mediators, MMP activity and cartilage biomarkers in equine joints with acute synovitis","volume":"41","author":"De Grauw","year":"2009","journal-title":"Equine Vet J"},{"key":"2026020922233269500_jvim15433-bib-0033","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.1365-2885.2007.00840.x","article-title":"Pharmacokinetics and metabolism of orally administered firocoxib, a novel second generation coxib, in horses","volume":"30","author":"Kvaternick","year":"2007","journal-title":"J Vet Pharmacol Ther"}],"container-title":["Journal of Veterinary Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvim.15433","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvim.15433","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jvim.15433","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/33\/2\/961\/66659077\/jvim15433.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/33\/2\/961\/66659077\/jvim15433.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T03:37:07Z","timestamp":1770694627000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jvim\/article\/33\/2\/961\/8448044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,1]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,3,1]]}},"URL":"https:\/\/doi.org\/10.1111\/jvim.15433","relation":{},"ISSN":["1939-1676"],"issn-type":[{"value":"1939-1676","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,3]]},"published":{"date-parts":[[2019,3,1]]},"assertion":[{"value":"2018-06-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-02-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}